On July 31st, the Bio-Thera Yonghe Phase 2 Expansion Project, which is located in Yonghe Development Zone, Huangpu District, Guangzhou City, Guangdong Province, undertaken by Morimatsu LifeSciences was successfully delivered.

The project covers the upstream production line of monoclonal antibody stock solution for mammalian cell culture, as well as the downstream supporting production process system and SCADA data acquisition system.

Morimatsu LifeSciences provided a wide spectrum of services for the project, involving detailed design, data acquisition system design, factory manufacturing, on-site installation, commissioning and verification. Morimatsu LifeSciences has effectively executed a comprehensive end-to-end solution encompassing design, procurement, factory manufacturing, FAT factory test, packaging, and shipping. This remarkable performance has been made possible owing to its proficient engineering management and design expertise, coupled with the adept supply chain deployment and top-notch manufacturing capabilities.

During the project execution process, the team from Morimatsu LifeSciences always has always kept communication with the client's representatives in a timely and efficient manner to gain a thorough knowledge of customer’s demands. All these efforts have enabled Morimatsu LifeSciences to provide the client with professional overall solutions, which effectively solved a wide array of problems otherwise troubled the client as they did in previous projects.

Despite the repeated interferences of several rounds Covid-19 in 2022, Morimatsu LifeSciences, leveraging its strong construction capabilities, overcame the difficulties and successfully completed the construction of 6 sets of 6000L bioreactors, stainless steel dispensing and storage systems, stainless steel replenishment systems, purification and ultrafiltration systems, CIP stations and inactivation systems, and other process modules. Thanks to these works, the on-site workload was reduced to a certain extent, thus shortening the overall project construction period and accelerating the start-up of the new production line for the client.

As a global biopharmaceutical company, Bio-Thera has always placed the well-being of patients as its primary core value, providing safe, effective, affordable and quality drugs through innovative R&D to meet the urgent therapeutic demands. This project will further enhance Bio-Thera's capabilities in production and R&D, thus benefiting more patients.

Benchmark set through quality products created with ingenuity. The successful delivery of this project once again demonstrates the excellent manufacturing strength and delivery capability of Morimatsu LifeSciences, which is of breakthrough significance and opens a new chapter in the cooperation between Morimatsu LifeSciences and Bio-Thera.

Bio-Thera Solutions, Ltd.

Bio-Thera Solutions, Ltd., a leading innovative, global biopharmaceutical company in Guangzhou, China. Adhering to the philosophy of "Innovation for Life", we are dedicated to researching and developing novel therapeutics for the treatment of cancer, autoimmune, cardiovascular diseases, and other serious unmet medical needs.

About Morimatsu LifeSciences

Morimatsu LifeSciences is a subsidiary of Morimatsu International Holdings Limited (Morimatsu International, stock code: 2155.HK), covering pharmaceutical, biopharmaceutical, FMCG, cosmetics, electronic chemicals and other industries, provides clients with "core equipment/Machinery + Value added + digitalized intelligence overall Plant Solutions and Service" (" MVP Solutions & Service"), mainly including Shanghai Morimatsu Pharmaceutical Equipment Engineering Co., LTD., Morimatsu (Suzhou) LifeSciences Co., LTD., Shanghai Morimatsu Biotechnology Co., LTD., Shanghai Mori-Biounion Technology Co.,Ltd. and Pharmadule Morimatsu AB., Morimatsu Pharmadule (Singapore) Private Limited as well as their subsidiaries. Morimatsu LifeSciences is focusing on the research and development, manufacturing, and sales of products in related fields.

Forward-Looking Statements

The information in this press release may include some forward-looking statements. Such statements are essentially susceptible to considerable risks and uncertainties. The use of "predicted", "believed", "forecast", "planned" and/or other similar words/phrases in all statements related to our company is to indicate that the statements are forward-looking ones. Our Company undertakes no obligation to constantly revise such predicted statements.

Forward-looking statements are based on our Company management's current perspectives, assumptions, expectations, estimations, predictions and understanding of future affairs at the time of the making of such statements. Such statements are not guarantees of future development and are susceptible to the impact of risks, uncertainties and other factors; some are beyond the control of our Company and unpredictable. Subject to the influence of future changes and development in our business, competition environment, political, economic, legal and social conditions, the actual outcomes may differ significantly from the information contained in the forward-looking statements.